Pathophysiologic bases for adjunctive therapies in the treatment and secondary prevention of acute myocardial infarction

Clinical Cardiology
D E Gutstein, V Fuster

Abstract

Postmyocardial infarction (MI) survival has been steadily improving. This improvement has been due, in part, to the actions of the adjunctive medical therapies for the treatment of MI. Aspirin, beta blockers, angiotensin-converting enzyme (ACE) inhibitors, and lipid-lowering agents have been shown to improve survival in the treatment and secondary prevention of MI. Nitrates have beneficial effects as well. These medications complement the reperfusion strategies through different mechanisms. Other adjunctive medical therapies, namely magnesium, antiarrhythmic agents, and calcium-channel blockers, have not been shown to improve mortality with routine post-MI use despite their theoretical benefits.

References

Jul 23, 1992·The New England Journal of Medicine·UNKNOWN Cardiac Arrhythmia Suppression Trial II Investigators
Jul 23, 1992·The New England Journal of Medicine·J LauT C Chalmers
Jan 30, 1992·The New England Journal of Medicine·V FusterJ H Chesebro
Jan 11, 1992·BMJ : British Medical Journal·K L WoodsL F Smith
Jul 19, 1990·The New England Journal of Medicine·P SmithI Holme
Aug 10, 1989·The New England Journal of Medicine·UNKNOWN Cardiac Arrhythmia Suppression Trial (CAST) Investigators
Nov 11, 1989·BMJ : British Medical Journal·P H HeldC D Furberg
Mar 1, 1985·Progress in Cardiovascular Diseases·S YusufP Sleight
Aug 18, 1988·The New England Journal of Medicine·UNKNOWN Multicenter Diltiazem Postinfarction Trial Research Group
Jan 1, 1988·Chest·H K Gold, R C Leinbach
Dec 1, 1988·Journal of the American College of Cardiology·V FusterJ H Chesebro
Mar 1, 1985·European Heart Journal·K S SalathiaD M Boyle
Sep 16, 1982·The New England Journal of Medicine·UNKNOWN E.P.S.I.M. Research Group
Dec 13, 1993·Archives of Internal Medicine·D G ZarembskiA C Caruso
Jan 1, 1993·Progress in Cardiovascular Diseases·M A Arsenian
Aug 1, 1993·Circulation·K NademaneeJ N Weiss
Apr 27, 1995·The American Journal of Cardiology·P A Poole-Wilson
Feb 15, 1995·The American Journal of Cardiology·M ShechterB Rabinowitz
Jan 1, 1994·European Heart Journal·M DellborgK Swedberg

❮ Previous
Next ❯

Citations

Sep 18, 1998·Emergency Medicine Clinics of North America·O W Hayes
May 15, 2013·The American Journal of Pathology·Coralie FontaineJean-François Arnal
Aug 21, 2019·International Journal of Molecular Sciences·Afonso Caricati-NetoFrancisco Sandro Menezes-Rodrigues
Jan 9, 2001·The Joint Commission Journal on Quality Improvement·A L Kosseff, S Niemeier

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.